

Practical Gynecology, 2nd Edition – Chapter 5 References

- *1. **Finer LB, Henshaw SK.** Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. *Perspect Sex Reprod Health.* 2006;38:91-96. This publication reports the most up-to-date assessment of unplanned pregnancy rates in the United States using the 2002 National Survey of Family Growth.
2. **Frost JJ, Sonfield A, Gold R, Ahmed F.** Estimating the impact of serving new clients by expanding funding for Title X. Guttmacher Institute Occasional Report No 33. November 2006. Available at <http://www.guttmacher.org/sections/index.php?page=reports> Retrieved May 30, 2007.
3. **Picardo CM, Nichols M, Edelman A, Jensen JT.** Women's knowledge and sources of information on the risks and benefits of oral contraception. *JAMWA* 58:112-116; 2003.
4. **Stewart FH.** Harper CC. Ellertson CE. Grimes DA. Sawaya GF. Trussell J. Clinical breast and pelvic examination requirements for hormonal contraception: Current practice vs evidence. *JAMA.* 2001;285:2232-9.
- *5. **World Health Organization.** Medical Eligibility Criteria for Contraceptive Use. Third Edition, 2004. Available at www.who.int. Retrieved May 30, 2007. *This resource is a "must-have" for all clinicians prescribing contraception. The WHO MEC provides a 1 to 4 grading system regarding the safety of each contraceptive method in women with common medical conditions, and is based on an extensive review of the literature and expert consensus statements. It is understandable, easily incorporated into clinical practice, and updated on a regular basis.*
6. **World Health Organization.** Comparing typical effectiveness of contraceptive methods. [Job Aid]. Geneva: World Health Organization, 2006. Available at: www.fhi.org/nr/shared/enFHI/Resources/EffectivenessChart.pdf. Accessed June 21, 2007
7. **Schwingl PJ, Shelton J.** Modeled estimates of myocardial infarction and venous thromboembolic disease in users of second and third generation oral contraceptives. *Contraception.* 1997;55:125-129.
8. **Hatcher RA, Trussell J, Stewart F, et al.** *Contraceptive Technology*, 17th ed. New York: Ardent Media, 1998.
9. **Speroff L, Darney PD.** *A Clinical Guide for Contraception*, 2nd ed. Baltimore: Williams and Wilkins; 1996.
10. **Moghissi KS, Syner FN, McBride LC.** Contraceptive mechanism of microdose norethindrone. *Obstet Gynecol.* 1973;41:585-94.
11. **Elstein M, Morris SE, Groom GV, et al.** Studies on low-dose oral contraceptives: cervical mucus and plasma hormone changes in relation to circulating D-norgestrel and 17-ethynyl estradiol concentrations. *Steril.* 1976;27:892-8.

- *12. **Trussell J, Vaughn B.** Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth. *Fam Plan Perspect.* 1999;31:64. *This is an updated assessment of typical-use contraceptive failure rates using the 1995 National Survey of Family Growth. In general, typical-use failure rates were significantly different (and worse) than the risk of failures found in published clinical trials.*
- *13. **van den Heuval MW, van Bragt AJM, et al.** Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. *Contraception.* 2005;72:168-174. *This is a very well executed prospective study comparing serum estrogen levels between oral contraceptives, the transdermal patch, and the vaginal ring. Patches were found to have higher average estrogen levels than pills or the ring but lower peak levels than pills. This data sparked major concern regarding the possibility of an increased risk of thrombosis but at this time there is little evidence to support this conjecture. Currently, there is no recommendation to change prescribing habits.*
14. **Verhoeven C, Dieben T.** The combined contraceptive vaginal ring, NuvaRing, and tampon co-usage. *Contraception.* 2004;69:197-199
15. **Verhoeven C, van den Heuval MW, Mulders TMT, Dieben T.** The contraceptive vaginal ring, NuvaRing, and antimycotic co-medication. *Contraception.* 2004;69:129-132.
16. **Dialogues in contraception.** *Contracep Fetal Risk.* 1991;3:1-8.
17. **Huggins GR, Cullins VE.** Fertility after contraception or abortion. *Fertil Steril.* 1990;54:559-73.
18. **Hormonal Contraception.** ACOG Technical Bulletin No. 198, Oct. 1994.
- *19. **Westhoff C, et al.** Bleeding patterns after immediate versus conventional oral contraceptive initiation: a randomized controlled trial. *Fertil Steril* 2003;79:322-329. This study helped to reinvigorate the movement to start women on their hormonal contraception immediately (Quickstart) instead of waiting for a traditional Sunday start. Not only does it shorten the time interval where a woman is at risk for pregnancy but Quickstart has no increased rates of breakthrough bleeding compared to traditional Sunday starts.
20. **Metabolic effects of oral contraceptives: fact vs. fiction.** In: Grimes DA, ed. *Contraception Report.* 1996;6:4-14.
21. **Klein BE, Moss SE, Klein R.** Oral contraceptives in women with diabetes. *Diabetes Care.* 1990;13:895-8.
22. **Garg SK, Chase HP, Marshall G, et al.** Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus. *JAMA.* 1994;271:1099-1102.

23. **Sullivan JM, Lobo RA.** Considerations for contraception in women with cardiovascular disorders. *Am J Obstet Gynecol.* 1993;168:2006–11.
24. **Stone SC.** Clinical challenge: oral contraceptives and hypertension. *Int J Fertil.* 1994;39:143–7.
25. **Wild RA.** Clinical challenge: the diabetic on oral contraceptives. *Int J Fertil.* 1994;39:148–52.
26. **Mestman JH, Schmidt-Sarosi C.** Diabetes mellitus and fertility control: contraception management issues. *Am J Obstet Gynecol.* 1993;168:2012–20.
27. **Loriaux DL, Wild RA.** Contraceptive choices for women with endocrine complications. *Am J Obstet Gynecol.* 1993;168:2021-6.
28. **Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH et al.** Combined oral contraceptives in women with systemic lupus erythematosus. *N Eng J Med.* 2005;353;24:2550-8.
29. **Comp PC, Zacur HA.** Contraceptive choices in women with coagulation disorders. *Am J Obstet Gynecol.* 1993;168:1990–3.
30. **Knopp RH, LaRosa JC, Burkman RT Jr.** Contraception and dyslipidemia. *Am J Obstet Gynecol.* 1993;168:1994–2005.
31. **Upton GV.** Lipids, cardiovascular disease, and oral contraceptives: a practical perspective. *Fertil Steril.* 1990;53:1–12.
32. **Breckwoldt M, Wieacker P, Geisthovel F.** Oral contraception in disease states. *Am J Obstet Gynecol.* 1990;163:2213–6.
33. **Kyos SL, Shoupe D, Douyan S, et al.** Effect of low-dose oral contraceptives on carbohydrate and lipid metabolism in women with recent gestational diabetes: results of a controlled, randomized, prospective study. *Am J Obstet Gynecol.* 1990;163:1822–7.
34. **Vessey M, Painter R.** Oral contraceptive use and benign gallbladder disease revisited. *Contraception.* 1994;50:167–73.
35. **Sanchez-Guerrero J, Uribe A, Jimenez-Santana L, Mestanza-Peralta M, Lara-Reyes P, Seuc A, Cravioto, M.** A trial of contraceptive methods in women with systemic lupus erythematosus. *N Engl J Med.* 2005;353:2539-2549.
36. **Petri M, Kim MY, Kalunian KC, et al, for the OC-SELENA trial.** Combined oral contraceptives in women with systemic lupus erythematosus. *N Engl J Med.* 2005;353:2550-2558.
37. **Ramcharan S.** Pellegrin FA, Ray RM, Hsu J-P. A prospective study of the side effects of oral contraceptives. Volume III—an interim report: a comparison of disease

occurrence leading to hospitalizations or death in users and nonusers of oral contraceptives. *J Reprod Med.* 1980;25:345–72.

38. **Further analyses of mortality in oral contraceptive users.** Royal College of General Practitioners' Oral Contraception Study. *Lancet.* 1981;1:541–6.

39. **Vessey M, Mant D, Smith A, Yeates D.** Oral contraceptives and venous thromboembolism: findings in a large prospective study. *Br Med J.* 1986;292:526.

40. **Grodstein F, Stampfer M, Goldhaber SZ, et al.** Prospective study of exogenous hormones and risk of pulmonary embolism in women. *Lancet.* 1996;348:983–7.

41. **Gerstman BB, Pip JM, Tomita DK, et al.** Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. *Am J Epidemiol.* 1991;133:32–7.

42. **Koster T, Small RA, Rosendaal FR, Helmerhorst FM.** Oral contraceptives and venous thromboembolism: a quantitative discussion of the uncertainties. *J Intern Med.* 1995;238:31–7.

43. **Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease.** World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. *Lancet.* 1995;346:1582–8.

44. **Jick H, Jick SS, Gurewich V, et al.** Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. *Lancet.* 1995;346:1589–93.

45. **Venous thromboembolic disease and combined oral contraceptives; results of an international multicentre case-control study.** World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. *Lancet.* 1995;346:1575–82.

46. **Spitzer WO.** The aftermath of a pill scare: regression to reassurance. *Hum Reprod Update.* 1999;5:736–45.

47. **Lidegaard O.** Thrombotic diseases in young women and the influence of oral contraceptives. *Am J Obstet Gynecol.* 1998;179:S62–7.

48. **Lidegaard O, Edstrom B, Kreiner S.** Oral contraceptives and venous thromboembolism: a case-control study. *Contraception.* 1998;57:291–301.

49. **Suissa S, Spitzer WO, Rainville B, et al.** Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. *Hum Reprod.* 2000;15:817–21.

50. **Farmer RDT, Lawrenson RA, Thompson CR, et al.** Population-based study of risk of venous thromboembolism associated with various oral contraceptives. *Lancet.* 1997;349:83–8.

51. **Tanis, BC, van den Bosch MA, Kemmeren JM, et al.** Oral Contraceptives and the Risk of Myocardial Infarction. *N Engl J Med.* 2001;345:1787-1793.
52. **Bousser MG.** Kittner SJ. Oral contraceptives and stroke. *Cephalalgia.* 2000;20:183-9
53. **Curtis K, Mohllajee A, Peterson HB.** Use of oral contraceptives among women with migraine and nonmigrainous headaches: a systematic review. *Contraception* 2006;73:189-194.
54. **Kamphuisen PW, Rosendaal FR.** Thrombophilia screening: a matter of debate. *Neth J Med* 2004;62:180-187.
55. **Jick SS, Kaye JA, et al.** Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 micrograms of ethinyl estradiol. *Contraception* 2006;73:223-8.
56. **Cole JA, Norman H, Doherty M, Walker A.** Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. *Obstet Gynecol* 2007;109:339-46.
57. **Blumenthal PD, McIntosh N.** Pocket guide for Family Planning Service Providers, 2nd ed. JHPIEGO Corporation, 1996.
58. **Porter JB, Jick H, Walker AM.** Mortality among oral contraceptive users. *Obstet Gynecol.* 1987;70:29–32.
59. **Porter JB, Hunter JR, Jick H, Stergachis A.** Oral contraceptives and nonfatal vascular disease. *Obstet Gynecol.* 1985;66:1–4.
60. **Krauss RM, Kurkman RT Jr.** The metabolic impact of oral contraceptives. *Am J Ob-stet Gynecol.* 1992;167:1177–84.
61. **Burkman RT, Robinson C, Moran-Kruszon D, et al.** Lipid and lipoprotein changes associated with oral contraceptive use: a randomized clinical trial. *Obstet Gynecol.* 1988;71:33.
62. **Godsland IF, Crook D, Simpson R, et al.** The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. *N Engl J Med.* 1990;323:1375–81.
63. **Adams MR, Clarkson TB, Koritnik DR, Nash HA.** Contraceptive steroids and coronary artery atherosclerosis in *Cynomolgus* macaques. *Fertil Steril.* 1987;47:1010–8.
64. **Clarkson TB, Shively CA, Morgan TM, et al.** Oral contraceptives and coronary artery atherosclerosis of *Cynomolgus* monkeys. *Obstet Gynecol.* 1990;75:217–22.
65. **Palatsi R, Hirvensalo E, Liukko P.** Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives. *Acta Derm Venereol (Stockh).* 1984;64:517–23.

66. **Phillips A.** Demarest K, Hahn DW, et al. Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins. *Contraception*. 1990;41:399–410.
67. **Archer DF.** Clinical and metabolic features of desogestrel: a new oral contraceptive preparation. *Am J Obstet Gynecol*. 1994;170:1550–5.
68. **Gutmann JN, Corson SL.** The new progestins: pharmacologic and clinical aspects. *Int J Fertil*. 1994;39:163–176.
69. **Derman RJ.** Oral contraceptives: androgenicity and estrogenicity. *Int J Fertil*. 1994;39(suppl 3):177–82.
70. **Fotherby K, Caldwell ADS.** New progestogens in oral contraception. *Contraception*. 1994;49:1–32
71. **Mishell DR Jr.** Noncontraceptive health benefits of oral steroidal contraceptives. *Am J Obstet Gynecol*. 1982;142:809.
72. **Kost K, Forrest JD, Harlap S.** Comparing the health risks and benefits of contraceptive choices. *Fam Plann Perspec*. 1991;23:54–61.
73. **Dialogues in Contraception 3: Therapeutic Uses of Oral Contraceptives.** Vol. 30, No. 3, 1991.
74. **Jones KP, Ravnikar VA, Tulchinsky D, Schiff I.** Comparison of bone density in amenorrheic women due to athletics, weight loss, and premature menopause. *Obstet Gynecol*. 1985;66:5.
75. **Sulak PJ, Cressman BE, Waldrop E, et al.** Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. *Obstet Gynecol* 1997; 89:179-183.
76. **Vercellini P, De Giorgi, Mosconi P, et al.** Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. *Fertil Steril* 2002;78:886.
77. **Glasier AF, Smith KB, van der Spuy ZM, et al.** Amenorrhea associated with contraception - an international study on acceptability. *Contraception* 2003;67:1-8.
- *78. **Miller L, Hughes JP.** Continuous oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. *Obstet Gynecol* 2003; 101:653-61. *One of the first randomized control trials to investigate continuous dosing.*
79. **Sulak PJ, Kuehl TJ, Coffe A, et al.** Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen. *Am J Obstet Gynecol* 2006;195:935-41.

80. **CDC/NICHD.** Oral contraceptives and endometrial cancer: combination oral contraceptive use and the risk of endometrial cancer. *JAMA.* 1987;257:6.
81. **Oral contraceptive use and the risk of endometrial cancer.** The Centers for Disease Control Cancer and Steroid Hormone Study. *JAMA.* 1983;249:1600–4.
82. **Oral contraceptive use and the risk of ovarian cancer.** The Centers for Disease Control Cancer and Steroid Hormone Study. *JAMA.* 1983;249:1596–9.
83. **Siskind V, Green A, Bain C, Purdie D.** Beyond ovulation: oral contraceptives and epithelial ovarian cancer. *Epidemiology.* 2000;11:106–10.
- *84. **Collaborative Group on Hormonal Factors in Breast Cancer.** Breast cancer and hormonal contraceptives: collaborative breast cancer reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. *Lancet* 1996;347:1713-1727. *In this publication, the currently available literature was reevaluated and finally alleviated the concern that exposure to hormonal contraceptives causes breast cancer. Use of hormonal contraception has no impact on the risk of breast cancer.*
85. **Schlesselman JJ.** Cancer of the breast and reproductive tract in relation to use of oral contraceptives. *Contraception.* 1989;40:1–38.
86. **Risk of cervical dysplasia in users of oral contraceptives, intrauterine devices or depotmedroxyprogesterone acetate.** The New England Contraception and Health Study Group. *Contraception.* 1994;50:431–41.
87. **Grimes DA.** Oral contraceptives and your older patient. *Dialog Contracept.* 1988;2:1–3.
88. **Connell EB.** Rational use of oral contraceptives in the perimenopausal woman. *J Reprod Med.* 1993;38:1036–40.
89. **Cambacciani M.** Spinetti A, Taponeco F, et al. Longitudinal evaluation of perimenopausal vertebral bone loss: effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism. *Obstet Gynecol.* 1994;83:392–6.
90. **Sulak PJ.** Age-related concerns of oral contraceptive use: the perimenopausal patient. *Int J Fertil.* 1994;39:158–62.
91. **Rosenberg MJ, Waugh MS, Burnhill MS.** Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation. *Fam Plann Persp.* 1998;30:89–92.
92. **McCann MF, Lotter LS.** Progestin-only oral contraception: a comprehensive review. *Contraception.* 1994;50(suppl I):SI-195.
93. **Chi IC.** The progestin-only pills and the levonorgestrel-releasing IUD: two progestin-only contraceptives [Review] [71 refs]. *Clin Obstet Gynecol.* 1995;38:872–89.

94. **Broome M, Fotherby K.** Clinical experience with the progestogen-only pill as a contraceptive method. *Br J Fam Plann.* 1990;16–84.
95. **Kaunitz AM.** Injectable contraception. *Clin Obstet Gynecol.* 1989;356–68.
96. **Kaunitz AM.** Long-acting injectable contraception with depot medroxyprogesterone acetate. *Am J Obstet Gynecol.* 1994;170:1543–9.
97. **Kaunitz AM, Mishell DR.** Progestin-only contraceptives: current perspectives and future directions. *Dialog Contracept.* 1994;4(2).
98. **Arias R, Jain JK, Brucker C, Ross D, Ray A.** Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg. *Contraception.* 2006;74:234-238.
99. **Cundy T, Evans M, Roberts H, et al.** Bone density in women receiving depot medroxyprogesterone acetate for contraception. *BMJ.* 1991;303:13–6.
100. **Cundy T, Farquhar CM, Cornish J, Reid IR.** Short-term effects of high dose oral medroxyprogesterone acetate on bone density in premenopausal women [see Comments]. *J Clin Endocrinol Metab.* 1996;81:1014–7.
101. **Cromer BA, Blair JM, Mahan JD, et al.** A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. *J Pediatr.* 1996;129:671–6.
102. **Cullins VE.** Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate [review] [57 refs]. *J Reprod Med.* 1996;41:428–33.
103. **Kaunitz AM.** Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians [Review] (55 refs). *Int J Fertil Womens Med.* 1998;43:73–83.
- *104. **World Health Organization.** WHO statement on hormonal contraception and bone health. July 2005. Available at: http://www.who.int/reproductive_health/family_planning/bone_health.html. This WHO statement is a well-balanced review of the literature on DMPA and bone loss and provides clinical recommendations for initiation and continuation of DMPA use.
105. **Bachrach L, Cundy T, Ott S.** Depot medroxyprogesterone acetate in teens: a risk for bone health? *Pediatrics.* 2000;106:1137-1138.
106. **Depot medroxyprogesterone acetate (DMPA) and risk of endometrial cancer.** WHO Collaborative Study of Neoplasia and Steroid Contraceptives. *Inter J Cancer.* 1991;49:186–90.
107. **Cullins VE.** Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate [review] [57 refs]. *J Reprod Med.* 1996;41:428–33.

108. **Mattson RH, Cramer JA, Caldwell BV, Siconolfi BC.** Treatment of seizures with medroxyprogesterone acetate: preliminary report. *Neurology*. 1984;34:1255–8.
109. **Legardy JK, Curtis KM.** Progestin-only contraceptive use among women with sickle cell anemia: a systematic review. *Contraception*. 2006;73:195-204.
110. **de Abood M, de Castillo Z, Guerrero F, Espino M, Austin KL.** Effect of depo-provera or microgynon on the painful crises of sickle cell anemia patients. *Contraception*. 1997;56:313-316.
111. **Jain J, Dutton C, Nicosia A, Wajszczuk C, Bode F, Mishell D.** Pharmacokinetics, ovulation suppression, and return to ovulation following a lower dose subcutaneous formulation of Depo Provera. *Contraception*. 2004;70:11-18
112. **Bahamondes L, Marchi NM, Nakagava HM, de Melo ML, Cristofaletti Mde L, Pellini E, Scozzafave RH, Petta C.** Self-administration with UniJect of the once-a-month injectable contraceptive Cyclofem. [Journal Article. Research Support, Non-U.S. Gov't] *Contraception*. 56(5):301-4, 1997 Nov. Wenzl R, van Beek A, Schnabel P, et al. Pharmacokinetics of Etonogestrel released from the contraceptive implant Implanon. *Contraception*. 1998;58:283-288.
113. **Wenzl R, van Beek A, Schnabel P, et al.** Pharmacokinetics of Etonogestrel released from the contraceptive implant Implanon. *Contraception*. 1998;58:283-288.
114. **Cherry S.** Implanon: the new alternative. *Austral Fam Physican*. 2002;31:897-900.
115. **Zheng SR, Zheng HM, Qian SZ, et al.** A long term study of the efficacy and acceptability of a single-rod hormonal contraceptive implant (Implanon) in healthy women in China. *Eur J Contracept Reprod Health Care*. 1999;4:85-93
116. **Peralta O, Diaz S, Croxatto H.** Subdermal contraceptive implants. *Steroid Biochem Molec Biol*. 1995;53(1-6):223-226.
117. **Brache V, Faundes A, Johansson E, et al.** Anovulation, inadequate luteal phase and poor sperm penetration in cervical mucus during prolonged use of Norplant implants. *Contraception*. 1985;31:261-273.
118. **Croxatto HB, Makarainen L.** The pharmacodynamics and efficacy of Implanon: an overview of the data. *Contraception*. 1998;58 (suppl):91S-97S.
119. **Croxatto HB.** Mechanisms that explain the contraceptive action of progestin implants for women. *Contraception*. 2002b;65:21-27.
120. **Makarainen L, van Beek A, Tuomivaara L, et al.** Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. *Fertil Steril* 1998; 69:714-721.
121. **Affandi B.** An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon. *Contraception*. 1998; 58 (6 suppl):99S-107S.

122. **Urbancsek J.** An integrated analysis of nonmenstrual adverse events with Implanon. *Contraception*. 1998; 58 (6 suppl):109S-115S.
123. **Berenson AB, Wiemann CM.** Patient satisfaction and side effects with levonorgestrel implant (Norplant) use in adolescents 18 years of age or younger. *Pediatrics*. 1993;92:257-260.
124. **Croxatto HB, Urbancsek J, Massai R, et al.** A multicentre efficacy and safety study of the single contraceptive implant Implanon. *Human Reproduction*. 1999;14:976-981.
125. **Bjarnadottir RI, Gottfredsdottir H, Sigurdardottir K, et al.** Comparative study of the effects of a progestogen-only pill containing desogestrel and an intrauterine contraceptive device in lactating women. *Br J Obstet Gynaecol*. 2001;108:1174-1180.
126. **Kiriwat O, Patanayindee A, Koetsawang S, et al.** A 4-year pilot study on the efficacy and safety of Implanon, a single rod hormonal contraceptive implant, in healthy women in Thailand. *Eur J Contracept Reprod Health Care*. 1998;3:85-91.
127. **Sivin I, Mishell D, Diaz S, et al.** Prolonged effectiveness of Norplant capsule implants: a 7-year study. *Contraception*. 2000;61:187-194.
128. **von Hertzen H, Piaggio G, Ding J, et al.** Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre, randomized trial. *Lancet*. 2002;360:1803-1810. This large multi-center randomized trial provides a comprehensive evaluation of both the efficacy and side effects of traditional dosing of progestin-only emergency contraception (Plan B, 1 pill every 12 hours x two doses) versus the new, streamlined dosing (2 pills x 1 dose). The streamlined dosing approach appears to be as effective as traditional dosing with no increase in side effects and potentially improves compliance.
129. **Piaggio G, von Hertzen H, Grimes DA, Van Look PF.** Timing of emergency contraception with levonorgestrel or the Yuzpe regimen. *Lancet* 1999;353:721.
130. **Task force on post-ovulatory methods of fertility regulation.** Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. *Lancet*. 1998;352: 428-33.
131. **Raine T, Harper C, Leon K, Darney P.** Emergency contraception: advance provision in a young, high-risk clinic population. *Obstet Gynecol* 2000;96:1-7.
132. **Trussell J, Rodriguez G, Ellertson C.** New estimates of the effectiveness of the Yuzpe regimen of emergency contraception. *Contraception*. 1998;5:363-9.
133. **Creinin MD.** A reassessment of efficacy of the Yuzpe regimen of emergency contraception. *Hum Reprod*. 1997;12:496-8.

134. **Mosher WD, Martinez GM, Chandra A, et al.** Use of contraception and use of family planning services in the United States: 1982-2002. *CDC Advance Data from Vital and Health Statistics* 2004, 350. Available at: www.cdc.gov/nchs/data/ad/ad350.pdf . Downloaded May 30, 2007.
135. **Sivan I.** IUDs are contraceptives, not abortifacients: a comment on research and belief. *Stud Fam Plan.* 1989;20:355–9.
136. **Anderson J, Rybog.** Levonorgestrel-releasing IUD in the treatment of menorrhagia. *Br J Obstet Gynecol.* 1990; 97:1–36.
137. **Gardner FJ, Konje JC, Abrams KR, et al.** Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. *Lancet* 2000;356:1711-1717.
138. **Suhonen S, Holmstrom T, Lahteenmaki P.** Three-year follow-up of the use of a levonorgestrel-releasing intrauterine system in hormone replacement therapy. *Acta Obstet Gynecol Scand.* 1997;76:145-150.
139. **Farley TM, Rosenberg MJ, Rowe PJ, et al.** Intrauterine devices and pelvic inflammatory disease: an international perspective. *Lancet.* 1992;339:785-8.
140. **Grimes DA, Schulz KF.** Antibiotic prophylaxis for intrauterine contraceptive device insertion. *Cochrane database Syst Rev.* 2000;2.
141. **Walsh T, Grimes DA, Frezieres R.** Randomised controlled trial of prophylactic antibiotics before insertion of intrauterine devices. IUD Study Group. *Lancet.* 1998;351:1005-1008.
142. **White MK, Ory HW, Rooks JB, Rochat RW.** Intrauterine device termination rates and the menstrual cycle day of insertion. *Obstet Gynecol.* 1980;55:220
143. **ACOG Practice Bulletin No 59, 2005.** Intrauterine Device.
144. **Donovan B.** Condoms and the prevention of sexually transmissible diseases [Review] [18 refs]. *Br J Med Hosp.* 1995;54:575–8.
145. **Lytle CD, Routson LB, Seahorn GB, et al.** An in vitro evaluation of condoms as barriers to a small virus. *Sex Transm Dis.* 1997;24:161–4.
146. **Van Damme L, Ramjee G, Alary M, et al.** Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomized control trial. *Lancet.* 2002;360:971-77.
147. **Drew WL, Blan M, Miner RC, Conant E.** Evaluation of the virus permeability of a new condom for women. *Sex Transm Dis.* 1990;17:110.
148. **Soper DE, Shoupe D, Shangold GA, et al.** Prevention of vaginal trichomoniasis by compliant use of the female condom. *Sex Transm Dis.* 1993;20:137–9.

149. **Fihn SD, Latham RH, Roberts P, et al.** Association between diaphragm use and urinary tract infection. *JAMA*. 1985;254:240–5.
150. **Kuyoh MA, Toroitich-Ruto C, Grimes DA, et al.** Sponge versus diaphragm for contraception. *Cochrane Database of Systematic Reviews* 2, 2007.
151. **Trussel J, Hatcher RA, Cates W.** Contraceptive failure in the United States: an update. *Stud Fam Plann*. 1990;21:51–4.
- *152. **Peterson HB, Xia Z, Hughes JM, et al.** The risk of pregnancy after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization. *Am J Obstet Gynecol*. 1996;174:1161–70. *This landmark study changed the widely-held belief that postpartum sterilization procedures had the highest failure rates when in fact the opposite is true.*
153. **Hankinson SE, Hunter DJ, Golditz GA, et al.** Tubal ligation, hysterectomy, and the risk of ovarian cancer: a prospective study. *JAMA*. 1993;270:2813–8.
154. **Gentile, et al.** Is there any evidence for a post-tubal sterilization syndrome? *Fertil Steril* 1998;69:179-86
155. **Kulier R, et al.** Minilaparotomy and endoscopic techniques for tubal sterilisation. *The Cochrance Database of Systemic Reviews* 2006, Issue 2.
156. **Soderstrom RM.** Sterilization failures and their causes. *Obstet Gynecol*. 1985;69:425-6
157. **Soderstrom et al.** Reducing bipolar sterilization failures. *Obstet Gynecol*. 1989;74:60-3.
158. **Peterson, et al.** Pregnancy after tubal sterilization with bipolar electrocoagulation. *Obstet Gynecol* 1999;94:163-7
159. **Hillis SD, et al.** Poststerilization regret: findings from the United States Collaborative Review of Sterilization. *Obstet Gynecol* 1999;93:889
160. **Raspa FR.** Complications of vasectomy. *Am Fam Phys*. 1993;48:1264–8.
161. **Pollack Am, Rarone M.** Male sterilization in gynecology and obstetrics. In: Sciarra J, ed. Philadelphia: Lippincott-Raven; 1999.
162. **Davis LE, Stockton MD.** No-scapel vasectomy. *Prim Care*. 1997;24:433–61.
163. **Haws JM, Morgan GT, Pollack AE, et al.** Clinical aspects of vasectomies performed in the United States in 1995. *Urology*. 1998;52:685–91.
164. **Pollack AE.** Vasectomy and prostate cancer. *Adv Contracept*. 1993; 9:181–6.

165. **Farley TMM, Meirik O, Mehta S, Waites GMH.** The safety of vasectomy: recent concerns. *Bull WHO.* 1993;71:413–9.
166. **Møller H, Knudsen LB, Lynge E.** Risk of testicular cancer after vasectomy: cohort study of over 73,000 men. *BMJ.* 1994;309:295–9.
167. **John EM, Whittemore AS, Wu AH, et al.** Vasectomy and prostate cancer: results from a multiethnic case-control study. *J Natl Cancer Inst.* 1995;87:662–9.
168. **National Institutes of Health.** Does vasectomy cause prostate cancer? *JAMA.* 1993;169: 2620.
169. **Wilcox AJ, Weinberg CR, Baird DD.** Timing of sexual intercourse in relation to ovulation: effects on the probability of conception, survival of the pregnancy, and sex of the baby [see Comments]. *N Eng J Med.* 1995;333:1517–21.
170. **Ryder B, Campbell H.** Natural family planning in the 1990s [see Comments] [Review] [33 refs]. *Lancet.* 1995;346:233–4.
171. **Grimes DA, Wallach M, eds.** *Modern Contraception: Updates from the Contraceptive Report.* Wayne, NJ: Emron; 244–7.
172. **Ramos R, Kennedy KI, Visness CM.** Effectiveness of lactational amenorrhoea in prevention of pregnancy in Manila, the Philippines: a noncomparative prospective trial. *BMJ.* 1996;313:909–12.
173. **Hight-Laukaran V, Labbok MH, Peterson AE, et al.** Multicenter study of the lactational amenorrhoea method (LAM). II Acceptability, utility, and policy implications. *Contraception.* 1997;55:337–46.